New combo therapy targets lung cancer brain spread

NCT ID NCT07304739

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of furmonertinib (a targeted pill), chemotherapy injected into the spine, and precise radiation for people with a specific type of lung cancer (EGFR mutation) that has spread to the brain and its lining. The goal is to see if this approach can control the cancer in the brain and help people live longer. About 30 adults who have not had prior treatment will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Meningeal Carcinomatosis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

CANGZHOU People's Hospital
RECRUITING

Cangzhou, Hebei, 061001, China
Tianjin Huanhu Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300350, China
Tianjin medical university cancer hospital and institute
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.